Loading...

APC anti-mouse Ly-6A/E (Sca-1) Antibody

Pricing & Availability
Clone
D7 (See other available formats)
Regulatory Status
RUO
Other Names
Sca-1
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
D7_APC_091207
C57BL/6 mouse splenocytes stained with D7 APC
  • D7_APC_091207
    C57BL/6 mouse splenocytes stained with D7 APC
Compare all formats See APC spectral data
Cat # Size Price Save
108111 25 µg ¥14,780
108112 100 µg ¥47,530
Description

Ly-6A/E, also known as Sca-1, is an 18 kD member of the Ly-6 multigene family. Ly6A/E is a glycosylphosphatidylinositol (GPI)-linked protein expressed on hematopoietic stem cells. In mice expressing the Ly-6.2 haplotype (e.g., AKR, C57BL, C57BR, DBA/2, SJL, SWR, and 129), Ly-6A/E is also expressed on peripheral B lymphocytes and thymic and peripheral T lymphocytes. Strains expressing the Ly-6.1 haplotype (e.g., BALB/c, CBA, C3H/He, DBA/1, and NZB) have low Ly-6A/E expression on resting peripheral lymphocytes. The expression of Ly-6A/E on lymphocytes is upregulated upon activation from both Ly6.1 and Ly6.2 haplotype mice. Ly-6A/E is thought to be involved in the regulation of both T and B cell responses.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
IL-2-dependent mouse T-cell line (CTL-L)
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

The D7 antibody has been reported to induce T cell activation and inhibit TCR-induced IL-2 production. Additional reported applications (for the relevant formats) include: Western blotting1,2, immunoprecipitation1, in vitro lymphocyte activation3-6, induction of redirected lysis7, induction of T cell inhibitory signalling8, immunofluorescence9, and immunohistochemical staining of acetone-fixed frozen sections13 and Bouin-fixed, paraffin-embedded samples9.

The two Sca-1 recognizing clones D7 and E13-161.7 have been shown to bind distinct epitopes due to the inability of D7 to block the binding of E13-161.7.14 

Application References

(PubMed link indicates BioLegend citation)
  1. Ortega G, et al. 1986. J. Immunol. 137:3240. (WB, IP)
  2. Palfree RGE, et al. 1986. Immunogenetics 23:197. (WB)
  3. Codias EK, et al. 1990. J. Immunol. 144:2197.
  4. Malek TR, et al. 1986. J. Exp. Med. 164:709.
  5. Codias EK, et al. 1990. J. Immunol. 145:1407.
  6. Ivanov V, et al. 1994. J. Immunol. 153:2394.
  7. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  8. Fleming T, et al. 1994. J. Immunol. 153:1955.
  9. van Bragt MPA, et al. 2005. Biol. Reprod. 73:634. (IF, IHC)
  10. Umland O, et al. 2007. J. Immunol. 178:4147.
  11. Cridland SO, et al. 2009. Blood Cell. Mol. Dis. 45:149. (FC) PubMed
  12. Pronk CJ, et al. 2011. J. Exp Med. PubMed
  13. English A, et al. 2000. J. Immunol. 165:3763. (IHC)
  14. Bamezai A and Rock KL. 1995. Proc. Natl. Acad. Sci. USA 92:4294.
  15. Wiesner DL, et al. 2015. PLoS Pathog. 11:1004701. PubMed
Product Citations
  1. Feng X, et al. 2023. Nat Commun. 14:3208. PubMed
  2. Alam A, et al. 2022. Cancer Cell. 40:153. PubMed
  3. Leinroth AP, et al. 2022. Cell Rep. 39:110785. PubMed
  4. Moiseeva V, et al. 2023. Nature. 613:169. PubMed
  5. Tang Y, et al. 2022. Dev Cell. 57:480. PubMed
  6. Li DD, et al. 2022. Cell Host Microbe. 30:530. PubMed
  7. Umland O, et al. 2007. J Immunol . 178:4147. PubMed
  8. Ju W, et al. 2020. J Biomed Sci. 27:91. PubMed
  9. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
  10. Shi Y, et al. 2020. Med Sci Monit. 26:e923328. PubMed
  11. Bo Yu et al. 2018. Cell stem cell. 23(2):193-209 . PubMed
  12. Mikami Y, et al. 2021. Immunity. 54(3):514-525.e6. PubMed
  13. Philpott J, et al. 2022. Immunohorizons. 6:366. PubMed
  14. Larouche JA, et al. 2021. eLife. 0.416666666666667. PubMed
  15. Nguyen N, et al. 2022. iScience. 25:103679. PubMed
  16. Hinterbrandner M, et al. 2021. JCI Insight. 6:e151797. PubMed
  17. Mann M, et al. 2018. Cell Rep. 25:2992. PubMed
  18. Yin N et al. 2019. Cancer Cell. 36(2):156-167 . PubMed
  19. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  20. Liu X, et al. 2021. eLife. 0.416666666666667. PubMed
  21. Yamamoto K, et al. 2021. Cell Reports. 36(8):109576. PubMed
  22. Fujino T, et al. 2021. Nat Commun. 12:1826. PubMed
  23. Vannini N, et al. 2019. Cell Stem Cell. 24:405. PubMed
  24. De S, et al. 2018. Development. 145. PubMed
  25. Endo Y, et al. 2020. FASEB J. 34:16086. PubMed
  26. Kunimoto H, et al. 2018. Cancer Cell. 33:44. PubMed
  27. Hillel–Karniel C, et al. 2020. Cell Reports. 30(3):807-819.e4.. PubMed
  28. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  29. Shcherbina A, et al. 2020. Cell Rep. 32:107964. PubMed
  30. Jungwirth N et al. 2018. Journal of molecular neuroscience : MN. 65(1):60-73 . PubMed
  31. Hou M, et al. 2020. Stem Cell Res Ther. 11:55. PubMed
  32. Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed
  33. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  34. Ferreirinha P, et al. 2022. Development. 149: . PubMed
  35. Hepler C et al. 2018. eLife. 7 pii: e39636. PubMed
  36. Ikram M, et al. 2018. Oncotarget. 9:2058. PubMed
  37. Tavakol DN, et al. 2021. Curr Protoc. 1:e275. PubMed
  38. Mizbani A, et al. 2016. Development. 143: 4137 - 4148. PubMed
  39. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  40. Gentek R, et al. 2018. Immunity. 48:1160. PubMed
  41. Goldstein JM et al. 2019. Cell reports. 27(4):1254-1264 . PubMed
  42. Luo H, et al. 2020. Cancer Cell. 36(6):645-659.e8.. PubMed
  43. Bastianutto C, et al. 2007. Cancer Res. 67:10112. PubMed
  44. Glotzbach J, et al. 2011. PLoS One. 6:e21211. PubMed
  45. Keerthivasan S, et al. 2021. Immunity. 54(7):1511-1526.e8. PubMed
  46. Luo H, et al. 2022. Mol Cell. 82:833. PubMed
  47. Wolock SL, et al. 2019. Cell Rep. 28:302. PubMed
  48. Singhal P, et al. 2016. Proc Natl Acad Sci U S A. 113: 122 - 127. PubMed
  49. Markworth JF, et al. 2020. JCI Insight. 5:00. PubMed
  50. Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed
  51. Wong J, et al. 2016. Sci Signal. 9: ra103. PubMed
  52. Vannini N, et al. 2016. Nat Commun. 7:13125. PubMed
  53. Zhang Y, et al. 2008. Mol Cell Biol. 28:1688. PubMed
  54. Thomson CA, et al. 2018. J Immunol. 201:215. PubMed
  55. Cohen I et al. 2018. Cell stem cell. 22(5):726-739 . PubMed
  56. Liu Q, et al. 2016. Cell Death Dis. 1.93125. PubMed
  57. Vogiatzi A, et al. 2021. Mol Cell Biol. 41:e0014921. PubMed
RRID
AB_313348 (BioLegend Cat. No. 108111)
AB_313348 (BioLegend Cat. No. 108112)

Antigen Details

Structure
Ly-6 multigene family, 18 kD
Distribution

Hematopoietic stem cells, activated T cells and B cells, subset of resting B cells and T cells

Function
Regulates B and T cell responses
Cell Type
B cells, Hematopoietic stem and progenitors, Mesenchymal Stem Cells, T cells
Biology Area
Immunology, Stem Cells
Antigen References

1. Rock KL, et al. 1989. Immunol. Rev. 111:195.
2. Morrison SJ, et al. 1994. Immunity 1:661.
3. Spangrude GJ, et al. 1988. J. Immunol. 141:3697.
4. Malek T, et al. 1986. J. Exp. Med. 164:709.

Gene ID
110454 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
Ly-6A/E
Specificity Alt (DOES NOT SHOW ON TDS):
Ly-6A/E
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about Ly-6A/E on UniProt.org
Go To Top Version: 3    Revision Date: 07/11/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account